Add BrightSurf on Google Email

Researchers criticize study calling for expansion of genetic testing for breast cancer

A recent study calling for expanded genetic testing for hereditary breast cancer has been criticized by researchers at the University of Cambridge. The criticism highlights methodological flaws in the study and potential conflicts of interest among its authors, leading to concerns about the accuracy and practicality of such tests.

SourceUniversity of Cambridge·JournalJournal of Clinical Oncology·DateJun 27, 2019

Do women regret embryo testing before IVF?

A study found that 94% of patients who underwent embryo genetic testing before IVF were glad to have the information, despite potentially disappointing results. The research suggests that even after a negative outcome, most women value the knowledge gained from embryo testing for reproductive planning.

SourceNorthwestern University·JournalHuman Reproduction·DateJun 21, 2019

Promise of liquid biopsy in cancer biomarker detection and prenatal screening

The article discusses the potential of liquid biopsy in cancer diagnosis, focusing on targeted disease diagnosis and detection of cancer biomarkers. Researchers have successfully detected specific genetic mutations using digital PCR, identifying promising biomarkers for various cancers, including melanoma and lung squamous cell carcinoma.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalGenetic Testing and Molecular Biomarkers·DateApr 22, 2019

Ovarian cancer patients undertested for mutations that could guide clinical care

A recent study found that fewer than a quarter of breast cancer patients and a third of ovarian cancer patients underwent genetic testing for cancer-associated mutations. The research, which analyzed data from over 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014, revealed substantial...

SourceStanford Medicine·JournalJournal of Clinical Oncology·DateApr 9, 2019

In breast-cancer prevention, race matters

A new study found that African-American women are less likely than white women to pursue potentially life-saving preventive care due to racial disparities in healthcare. High-risk black women were also less aware of their options and at a disadvantage when it came to getting access to information about prevention.

SourceOhio State University·JournalEthnicity and Health·DateJan 14, 2019

Patient re-contact after revision of genomic test results: A new ACMG points to consider

The American College of Medical Genetics and Genomics (ACMG) has released new guidelines to help providers develop policies/procedures for re contacting patients after revising genomic test results. The guidelines aim to address the complex questions surrounding patient re contact, including legal, ethical, and practical issues.

SourceAmerican College of Medical Genetics and Genomics·JournalGenetics in Medicine·DateJan 8, 2019

New approach will help geneticists identify genes responsible for complex traits

Researchers developed SPAEML, a statistical approach that can accurately detect the underpinnings of simulated complex traits. The method was tested on datasets similar to Alzheimer's disease and flower structure in corn, identifying simulated markers and distinguishing between additive and interacting loci.

Who needs genetic testing for breast cancer?

According to Dr. Holly Pederson, genetic testing can help identify patients at risk of breast cancer and reduce their chances of survival. The presentation highlights the importance of early screening and advances in cancer genetics, making it possible to save lives through preventive medications and surgical procedures.

Expert: Keep up with latest discoveries through automated updates in reporting genetic test results

A new model is proposed to generate ongoing automated updates for genetic test results, allowing clinicians to better communicate relevant information to patients. This could enable personalized medicine by providing continuous interaction between clinics and labs, reanalysis of changing data, and more accurate diagnoses.

SourceChildren's Hospital of Philadelphia·JournalJAMA Pediatrics·DateOct 1, 2018

PGDx machine learning approach outperforms existing mutation detection methods in study

A study published in Science Translational Medicine shows that PGDx's CerebroTM technology can detect tumor-specific mutations with higher sensitivity and positive predictive value compared to existing methods. This improvement is crucial for accurate treatment decisions, particularly for biomarkers like tumor mutation burden.

SourcePure Communications Inc.·JournalScience Translational Medicine·DateSep 5, 2018